Ono Pharmaceutical Co., Ltd.
Fiscal Year Ending March 2027 — Second Quarter (Interim) Financial Summary [IFRS] (Consolidated)
Interim consolidated results: Revenue 232,504 million yen (YoY -9.6%), core operating profit 736 million yen, interim profit attributable to owners of parent 44,930 million yen. Full-year outlook unchanged from prior forecast. Dividend policy maintained at 40 yen at the end of the second quarter and 80 yen for the full year. Core adjustments include amortization of intangible assets and fair value inventory adjustments.
Key Figures
- Revenue: 232,504 million yen
- Operating Income: 57,907 million yen
- Interim Profit: 45,032 million yen
AI要約
Business Performance Overview
IFRS-based revenue for the interim period amounted to 232,504 million yen (YoY -9.6%), affected by declines in product sales both domestically and internationally. On a core basis, core operating profit was 736 million yen and core interim profit was 56,800 million yen (year-on-year increase), illustrating divergences between IFRS and core measures. Supplementary presentation materials for the results are available.
Outlook and Dividends
Full-year earnings guidance is maintained at the previously announced forecast. The dividend policy remains 40 yen at the end of the first quarter, 40 yen at the end of the second quarter, and 80 yen for the full year. The financial summary notes that, despite impacts such as the termination of the co-promotion agreement for Forxiga, the company plans to maintain stable overall cash flows.
Revenue Trend
Operating Income Trend
Interim Profit Trend
Core Profit Margin Trend
Dividend Policy
Ono Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
